TD Cowen Initiates Coverage On Nektar Therapeutics with Buy Rating

TD Cowen analyst Marc Frahm has initiated coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating. This marks a significant endorsement for the company as it seeks to enhance its market position.